

10-18-2001

101876796
PATENTS ONLY

U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

DOCKET NO.: 112902.600	PATENTS ONLY	Patent and Trademark Office
To the Honorable Commissioner of Patents and	Trademarks: Please record the attached original documents	or copy thereto:
Name of conveying party(ies): Pharmacia Biosystems AB	2. Name and address of receiving party(ies	s):
' ' '	Name: Axis Biochemicals ASA	4
	Address: <u>Ulvenveien 87</u>	
Additional name(s) of conveying party(ies) attached? _ Yes		
3. Nature of conveyance:	N-0510, Oslo, Norway	
X Assignment Merger		
Security Agreement Change of Name		
Other		
Execution Date: July 1, 1999	Additional name(s) & address(es) attached	? _ Yes X No
If the document is being filed together with a new applicat A. Patent Application No(s). 4,826,776	B. Patent No(s).	
Additiona	al numbers attached? Yes X No	
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents	s involved:1
Name: PEPPER HAMILTON LLP	7. Total fee (37 CFR 3.41)	\$ <u>40.00</u>
Internal Address:	X Enclosed	
	Authorized to be charged to deposit	account
Street Address: 600 Fourteenth Street, N.W.	8. Deposit account number:	
	50-0436	
City: Washington State: DC ZIP: 2000	15-2004	
1	DO NOT USE THIS SPACE	
Statement and signature. To the best of my knowledge and belief, the forego the original document.	oing information is true and correct and any attached copy is	a true copy of
Corinne M. Pouliquen, Reg. No. 35,753 Name and Registration No. of Person Signing	Signature Total number of pages incl	October 10, 2001 Date luding cover sheet: 3
CMB No. 0851-0011 (exp. 4/94)		

10/17/2001 DBYRHE 000

00000160 4826776

01 FC:581

40.00 DP

PATENT REEL: 012243 FRAME: 0571 - 1 -

S017-423.605

ASSIGNMENT

WHEREAS, Pharmacia Biosystems AB has made a certain new and useful invention as set forth in an application for United Stated Letters Patent, entitled <u>METHOD OF DETERMINING HYALURONIC ACID</u>, AND A REAGENT KIT FOR SAID <u>METHOD</u>, for which a patent for a United States Letters Patent was issued on May 2, 1989, and identified by United States Patent Number 4,826,776;

AND WHEREAS, Axis Biochemicals ASA, a corporation established under the laws of Sweden and having an address of Axis Biochemicals ASA, Ulvenveien 87, P.O. Box 206 Okern, N-0510, Oslo, Norway, is desirous of acquiring the entire right, title and interest in and to said invention, including the right to sue for past infringement, and in and to any and all Letters Patent of the United States and foreign countries which may be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, we do hereby sell, assign, transfer and set over unto Axis Biochemicals ASA, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention, including the right to sue for past infringement, as set forth in the above-mentioned application, including any continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof, and in and to any and all patents of the United States and foreign countries which may be issued for said invention;

UPON SAID CONSIDERATIONS, we hereby agree with the said assignee that we will not execute any writing or do

PATENT REEL: 012243 FRAME: 0572 * { any act whatsoever conflicting with these presents, and that we will, at any time upon request, without further or additional consideration but at the expense of said assignee, execute such additional assignments and other writings and do such additional acts as said assignee may deem necessary or desirable to perfect the assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining original, divisional, continuations, continuations-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the assigns and legal representatives of assignor and assignee;

AND we request the Commissioner of Patents and Trademarks to issue any Letters Patent of the United States which may be issued for said invention to said Axis Biochemicals ASA, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

NAME: Fredrik Berg Per Åberg

TITLE: VP, Asa General Couns Managing Director

SIGNATURE: July 1, 1999

PATENT REEL: 012243 FRAME: 0573

RECORDED: 10/10/2001